Skip to main content

Miyabeacin: A new cyclodimer presents a potential role for willow in cancer therapy

Ward, Jane L., Wu, Yanqi, Harflett, Claudia, Onafuye, Hannah, Corol, Delia, Lomax, Charlotte, Macalpine, William J., Cinatl Jr., Jindrich, Wass, Mark N., Michaelis, Martin, and others. (2020) Miyabeacin: A new cyclodimer presents a potential role for willow in cancer therapy. Scientific Reports, 10 . E-ISSN 2045-2322. (doi:10.1038/s41598-020-63349-1) (KAR id:81106)

Abstract

Willow (Salix spp.) is well known as a source of medicinal compounds, the most famous being salicin, the progenitor of aspirin. Here we describe the isolation, structure determination, and anti-cancer activity of a cyclodimeric salicinoid (miyabeacin) from S. miyabeana and S. dasyclados. We also show that the capability to produce such dimers is a heritable trait and how variation in structures of natural miyabeacin analogues is derived via cross-over Diels-Alder reactions from pools of ortho-quinol precursors. These transient ortho-quinols have a role in the, as yet uncharacterised, biosynthetic pathways around salicortin, the major salicinoid of many willow genotypes.

Item Type: Article
DOI/Identification number: 10.1038/s41598-020-63349-1
Uncontrolled keywords: Secondary metabolism; solution-state NMR
Subjects: R Medicine > RM Therapeutics. Pharmacology
Divisions: Divisions > Division of Natural Sciences > Biosciences
Depositing User: Martin Michaelis
Date Deposited: 04 May 2020 10:36 UTC
Last Modified: 04 Mar 2024 18:32 UTC
Resource URI: https://kar.kent.ac.uk/id/eprint/81106 (The current URI for this page, for reference purposes)

University of Kent Author Information

  • Depositors only (login required):

Total unique views for this document in KAR since July 2020. For more details click on the image.